Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) EBT (2018 - 2025)

10x Genomics' EBT history spans 8 years, with the latest figure at -$15.2 million for Q4 2025.

  • For Q4 2025, EBT rose 68.6% year-over-year to -$15.2 million; the TTM value through Dec 2025 reached -$39.9 million, up 77.54%, while the annual FY2025 figure was -$39.9 million, 77.54% up from the prior year.
  • EBT for Q4 2025 was -$15.2 million at 10x Genomics, up from -$28.2 million in the prior quarter.
  • Across five years, EBT topped out at $37.0 million in Q2 2025 and bottomed at -$91.7 million in Q3 2023.
  • The 5-year median for EBT is -$35.8 million (2024), against an average of -$34.1 million.
  • The largest annual shift saw EBT plummeted 541.0% in 2022 before it surged 199.78% in 2025.
  • A 5-year view of EBT shows it stood at -$16.0 million in 2021, then decreased by 2.61% to -$16.4 million in 2022, then plummeted by 183.94% to -$46.6 million in 2023, then decreased by 3.82% to -$48.4 million in 2024, then surged by 68.6% to -$15.2 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's EBT are -$15.2 million (Q4 2025), -$28.2 million (Q3 2025), and $37.0 million (Q2 2025).